A5023117613- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Bladder and Urothelial Cancer Treatments
- Pharmacogenetics and Drug Metabolism
- Schizophrenia research and treatment
- Treatment of Major Depression
- Ferroptosis and cancer prognosis
- Health Systems, Economic Evaluations, Quality of Life
- Pharmacovigilance and Adverse Drug Reactions
Istituto Oncologico Veneto
2020-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2023
Non-clear cell renal carcinoma (nccRCC) is a heterogeneous group of cancer. Treatment recommendations are extrapolated from ccRCC and lack solid evidence. Here, we review advanced nccRCC patients treated at our institute.We collected retrospective data on all pts the Istituto Oncologico Veneto January 2008. We compared overall response rate (ORR), progression free survival (PFS) (OS) according to histological subtypes type systemic treatments. Kaplan-Meier method, log-rank test Cox...
Second- or third-line treatment options for metastatic renal cell carcinoma (mRCC) have dramatically changed in the last few years. There are no criteria choice between nivolumab and cabozantinib, which both demonstrated overall survival (OS) gain pivotal trials. We conducted an analysis of oncological outcomes patients treated Veneto Region (Italy), studying different sequences TKI-nivolumab-cabozantinib TKI-cabozantinib-nivolumab a publicly funded healthcare system. retrospective,...
647 Background: Cabozantinib (CABO) is an oral tyrosine kinase inhibitor registered for the treatment of metastatic renal cell carcinoma (mRCC) first or subsequent lines. Tolerability in real world elderly patients poorly documented. G8 a short test vulnerability gaining increased interest as screening tool trials geriatric oncology. Methods: ZEBRA/MEET-URO 9 was prospective multicenter study safety and activity CABO administered to pts ≥70 years with mRCC, either lines treatment, until...
637 Background: The combination of neutrophil to lymphocyte (NLR), bone metastases and IMDC score in the novel prognostic Meet-URO has shown a higher performance than alone mRCC pts receiving ≥2 nd line nivolumab or cabozantinib two retrospective analyses 1 st nivolumab-ipilimumab real-world prospective study [http://bit.ly/Meet-URO15_score]. Further validation is needed since this represents an easy tool for clinical practice with no additional costs. Methods: A analysis elderly (≥70 yo)...
648 Background: The oral tyrosine kinase inhibitor Cabozantinib (CABO) is frequently used to treat patients with metastatic RCC. Polypharmacy common in elderly pts, thus several drug-drug interactions (DDIs) cabozantinib may ensue. Methods: ZEBRA /MEET-URO 9 was a prospective, real world trial enrolling pts ≥ 70 years mRRC treated CABO at 13 Italian Oncology Centers. All concomitants drugs administered were collected and categorized according active principles indication. DDIs identified...
290 Background: Second (2L) or third-line (3L) treatment options for mRCC have dramatically changed in the last years. The standard of care as per Italian Regulatory Agencies approvals is N C. To date, there are no criteria choice between and C, which both demonstrated OS gain pivotal trials. Methods: We planned a retrospective, real world analysis use C 2L 3L 17 Oncology Units Veneto Region. All consecutive patients (pts) with treated advanced setting 2017-2018 were included. Results:...